ChemotherapyNCT06976450
Evaluating the Effectiveness of ChemoNurs: A Mobile Chemotherapy Drug Guide for Oncology Nurses
A study testing ChemoNurs Mobile Application Group and Personal Smartphone in people with Chemotherapy, run by Koç University at 1 site in Turkey (Türkiye).
Trial summary
This study aimed to evaluate the effectiveness of a mobile chemotherapy drug guide application, ChemoNurs, developed for oncology nurses, in improving their knowledge and attitudes toward chemotherapy practices. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Chemotherapy
- What is being tested?
- ChemoNurs Mobile Application Group and Personal Smartphone
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 59 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Aug 2023to 1 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Actively administering chemotherapy treatments
- Having knowledge of how to use an Android or iOS smartphone
- Possessing mobile literacy
- Working in oncology clinics for a duration of 0-12 months
- Volunteering to participate in the study
Who cannot join
- Not having completed the orientation process in oncology clinics
- Not having administered chemotherapy
- Incomplete responses in the data collection forms
- Willingness to withdraw at any stage of the study
- Participation in the Oncology Nursing Certification Program
- Prior attendance in courses or training sessions related to chemotherapy drugs
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Hacettepe University Oncology Hospital
Ankara, Altındağ, 06230
About this study
Official title: Evaluating the Effectiveness of ChemoNurs: A Mobile Chemotherapy Drug Guide for Oncology Nurses - A Randomized Controlled Trial
This study aimed to evaluate the effectiveness of a mobile chemotherapy drug guide application, ChemoNurs, developed for oncology nurses, in improving their knowledge and attitudes toward chemotherapy practices.
H1: The mobile chemotherapy drug guide developed for oncology nurses increases their knowledge related to chemotherapy.
H2: The mobile chemotherapy drug guide developed for oncology nurses promotes the development of positive attitudes toward chemotherapy.
H3: The mobile chemotherapy drug guide developed for oncology nurses increases their satisfaction.
- Conditions
- Chemotherapy
- Being tested
- ChemoNurs Mobile Application Group, Personal Smartphone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChemoNurs Mobile Application GroupOther
Participants in the mobile app group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. U
Personal SmartphoneDevice
Used by participants to access and interact with the CHEMONURS mobile application during the study period.
| Study group | Role | What they receive |
|---|---|---|
| Application Group | Experimental | Participants in the experimental group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. Receives: Other: ChemoNurs Mobile Application Group; Device: Personal Smartphone |
| Standard Practice | No intervention | Participants in the control group were oncology nurses working at Hacettepe University Oncology Hospital who continued with their routine clinical duties without access to the CHEMONURS mobile application or any additional educational intervention. After completing the baseline assessment using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, no further intervention was provided. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months, in parallel with the experimental group, to evaluate changes over time in the absence of the mobile application. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Chemotherapy Knowledge Score
This outcome evaluates the improvement in oncology nurses' knowledge of chemotherapy administration, assessed through the Chemotherapy Practice Knowledge Scale for Oncology Nurses. The items are scored to assess nurses' knowledge related to chemotherapy practices using a 3-point Likert scale: "I have knowledge = 3," "I am unsure = 2," and "I have no knowledge = 1." The scale consists of 44 items and four subdimensions. The total score ranges from a minimum of 44 to a maximum of 132, with higher scores indicating greater knowledge regarding chemotherapy administration.
Measured: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)
Change in Attitudes Toward Chemotherapy Practices
This outcome measures changes in the attitudes of oncology nurses toward chemotherapy practices, using the Attitude Scale for Oncology Nurses Regarding Chemotherapy Practices. This scale was developed by Khan et al. (2012) to evaluate the attitudes of cancer nurses toward chemotherapy practices. It is a 4-point Likert-type scale with the following response options: 4 = Strongly Agree, 3 = Agree, 2 = Disagree, 1 = Strongly Disagree. The scale consists of two subdimensions: negative attitude (6 items) and positive attitude (4 items). The items under the negative attitude subdimension are reverse-scored when calculating the total score. The overall score ranges from a minimum of 10 to a maximum of 40, with higher scores indicating more positive attitudes toward chemotherapy practices.
Measured: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)
Secondary outcomes (2)
Mobile Application Usability
Evaluation of the usability of the CHEMONURS mobile application as assessed by the Mobile Application Usability Scale at Month 3 and Month 6. The scale was created by Hoehle et al. (2016), and its Turkish adaptation was made by Güler in 2019. This tool provides information about the colors, text styles, font sizes, transitivity, application management, etc., used in the mobile application. The scale is a 7-point Likert-type measurement tool and consists of a total of 40 questions. The minimum score is 40, and the maximum score is 280, with higher scores indicating better usability.
Measured: Month 3 and Month 6
Nurses' Satisfaction with CHEMONURS Application
Nurses' overall satisfaction with the CHEMONURS mobile application, assessed using the Satisfaction Scale at the end of the study (Month 6). To evaluate cancer nurses' satisfaction with the ChemoNurs mobile application, they were asked at the end of the sixth month to rate their satisfaction on a scale from 1 to 10, where 1 = Not at all satisfied and 10 = Very satisfied. Higher scores indicate better satisfaction.
Measured: Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2025
- Study start1 Aug 2023
- Primary completion1 Aug 2024
- Study completion1 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ChemotherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 59 participants (actual)
Sponsor and investigators
- Lead sponsor
- Koç University
- Sponsor type
- University, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Responsible party
- Principal investigator, Enes Simsek, Koç University
- Investigators
- Remziye Semerci Şahin, Assistant professor, Study director, Koç University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06976450
- Sponsor's protocol ID
- 2022.216.IRB3.099
- Status last verified
- May 2025
- First submitted
- 9 May 2025
- Last updated
- 2 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Effectiveness of ChemoNurs: A Mobile Chemotherapy Drug Guide for Oncology Nurses - A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06976450
- Acronym / sponsor ID
- 2022.216.IRB3.099
- Conditions
- Chemotherapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 59 participants (actual)
- Lead sponsor
- Koç UniversityUniversity, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 1 Aug 2024 (actual)
- Study completion
- 1 May 2025 (actual)
- First posted
- 16 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate the effectiveness of a mobile chemotherapy drug guide application, ChemoNurs, developed for oncology nurses, in improving their knowledge and attitudes toward chemotherapy practices.
H1: The mobile chemotherapy drug guide developed for oncology nurses increases their knowledge related to chemotherapy.
H2: The mobile chemotherapy drug guide developed for oncology nurses promotes the development of positive attitudes toward chemotherapy.
H3: The mobile chemotherapy drug guide developed for oncology nurses increases their satisfaction.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Application Group | Experimental | Other: ChemoNurs Mobile Application Group, Device: Personal SmartphoneParticipants in the experimental group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. |
| Standard Practice | No intervention | –Participants in the control group were oncology nurses working at Hacettepe University Oncology Hospital who continued with their routine clinical duties without access to the CHEMONURS mobile application or any additional educational intervention. After completing the baseline assessment using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, no further intervention was provided. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months, in parallel with the experimental group, to evaluate changes over time in the absence of the mobile application. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Actively administering chemotherapy treatments
- Having knowledge of how to use an Android or iOS smartphone
- Possessing mobile literacy
- Working in oncology clinics for a duration of 0-12 months
- Volunteering to participate in the study
Key exclusion criteria (6 listed)
- Not having completed the orientation process in oncology clinics
- Not having administered chemotherapy
- Incomplete responses in the data collection forms
- Willingness to withdraw at any stage of the study
- Participation in the Oncology Nursing Certification Program
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChemoNurs Mobile Application GroupParticipants in the mobile app group were oncology nurses employed at Hacettepe University Oncology Hospital who were provided access to CHEMONURS, a mobile chemotherapy drug guide application developed to support clinical decision-making and professional development. After completing a demographic form and baseline assessments using the Chemotherapy Practice Knowledge Scale and the Attitude Scale for Chemotherapy Practices, participants received a demo version of the app via a WhatsApp link. They were instructed to download the application onto their personal smartphones and use it freely over a six-month period during their routine clinical practice. No restrictions were placed on usage frequency to reflect real-world applicability; usage was monitored through embedded app analytics and nurse feedback. Daily reminders and follow-up communications were used to encourage continued engagement. Follow-up assessments of knowledge and attitudes were conducted at the 3rd and 6th months. U | Other | Application Group |
| Personal SmartphoneUsed by participants to access and interact with the CHEMONURS mobile application during the study period. | Device | Application Group |
Primary outcome
Change in Chemotherapy Knowledge Score
Time frame: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)
This outcome evaluates the improvement in oncology nurses' knowledge of chemotherapy administration, assessed through the Chemotherapy Practice Knowledge Scale for Oncology Nurses. The items are scored to assess nurses' knowledge related to chemotherapy practices using a 3-point Likert scale: "I have knowledge = 3," "I am unsure = 2," and "I have no knowledge = 1." The scale consists of 44 items and four subdimensions. The total score ranges from a minimum of 44 to a maximum of 132, with higher scores indicating greater knowledge regarding chemotherapy administration.
Change in Attitudes Toward Chemotherapy Practices
Time frame: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)
This outcome measures changes in the attitudes of oncology nurses toward chemotherapy practices, using the Attitude Scale for Oncology Nurses Regarding Chemotherapy Practices. This scale was developed by Khan et al. (2012) to evaluate the attitudes of cancer nurses toward chemotherapy practices. It is a 4-point Likert-type scale with the following response options: 4 = Strongly Agree, 3 = Agree, 2 = Disagree, 1 = Strongly Disagree. The scale consists of two subdimensions: negative attitude (6 items) and positive attitude (4 items). The items under the negative attitude subdimension are reverse-scored when calculating the total score. The overall score ranges from a minimum of 10 to a maximum of 40, with higher scores indicating more positive attitudes toward chemotherapy practices.
2 secondary outcomes
Mobile Application Usability
Time frame: Month 3 and Month 6
Nurses' Satisfaction with CHEMONURS Application
Time frame: Month 6
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Chemotherapy
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Thrombotic Thrombocytopenic Purpura (TTP)
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Remziye Semerci Şahin, Assistant professor study director
Koç University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ChemoNurs Mobile Application Group and Personal Smartphone in people with Chemotherapy, run by Koç University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Chemotherapy Knowledge Score (time frame: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2025.